Ventana CLDN18 (43-14A) RxDx Assay
Qualitative IHC assay using anti-CLDN18 (43-14A) to detect CLDN18.2 protein expression in FFPE gastric and GEJ adenocarcinoma tissue for treatment planning.
Casandra.ai provides a unified ordering experience so you can request this test directly from the performing lab, without changing your workflow.
Ordering is available where Casandra has an active integration with the performing lab. Labs that offer this test can connect with us to enable digital ordering.
About this test
VENTANA CLDN18 (43-14A) RxDx Assay is an FDA-approved, qualitative immunohistochemistry test that uses a rabbit monoclonal anti-CLDN18 antibody to detect CLDN18.2 protein expression in FFPE gastric and gastroesophageal junction adenocarcinoma tissue. It classifies tumors as CLDN18.2 positive or negative to support selection of CLDN18.2-targeted treatment strategies.
Where this test fits
| Indication | Biomarker | Biomarker details | Therapy (Select a therapy to open its FDA-approved testing pathway) |
|---|---|---|---|
| Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | Claudin 18 (CLDN18) | Claudin 18 (CLDN18) protein expression (≥75% viable tumor cells (% TC) staining) | VYLOY |
IVD Manufacturer
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalized healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
Order this test
If your organization is connected to Casandra, you can place an electronic order forVentana CLDN18 (43-14A) RxDx Assay directly from your existing workflow.
Casandra connects providers, labs, and sponsored programs so that companion diagnostics can be ordered consistently and documented cleanly, regardless of which system you start from.